EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.

Bower, M; Newlands, E S; Holden, L; Short, D; Brock, C; Rustin, G J; Begent, R H; Bagshawe, K D

Bower, M; Newlands, E S; Holden, L; Short, D; Brock, C; Rustin, G J; Begent, R H; Bagshawe, K D.

Affiliation

Bower M; Medical Oncology Unit, Charing Cross Hospital, London, United Kingdom. m.bower@cxwms.ac.uk

J Clin Oncol ; 15(7): 2636-43, 1997 Jul.

Article in En | MEDLINE | ID: mdl-9215835

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Trophoblastic Neoplasms/drug therapy; Uterine Neoplasms/drug therapy; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Cohort Studies; Cyclophosphamide/administration & dosage; Dactinomycin/administration & dosage; Drug Administration Schedule; Etoposide/administration & dosage; Female; Humans; Methotrexate/administration & dosage; Middle Aged; Pregnancy; Risk; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine/administration & dosage

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Uterine Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Trophoblastic Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Middle aged / Pregnancy Language: En Journal: J Clin Oncol Year: 1997 Document type: Article Affiliation country: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links